3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
Interventions
Carboplatin
98
Pemetrexed
70
pembrolizumab
68
Cisplatin
59
Paclitaxel
54
Docetaxel
45
Gemcitabine
37
Erlotinib Hydrochloride
24
Nivolumab
23
osimertinib
17
Bevacizumab
17
durvalumab
14
Cetuximab
13
130-nm albumin-bound paclitaxel
13
Gefitinib
11
Etoposide
11
Drug Therapy
11
Ipilimumab
9
Injections
9
Albumin-Bound Paclitaxel
9
Vinorelbine
8
Radiotherapy
8
motexafin gadolinium
7
capmatinib
7
atezolizumab
7
epacadostat
6
Taxes
6
Cyclophosphamide
6
vandetanib
5
entinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Neoplasms
×
JDQ443
×
Clear all
NCT05132075
2026-06-02
KontRASt-02
Novartis
Phase 3
Active not recruiting
95 enrolled
NCT05445843
2026-05-14
KontRASt-06
Novartis
Phase 2
Active not recruiting
95 enrolled
20 charts
NCT04699188
2026-03-18
KontRASt-01
Novartis
Phase 1/2
Active not recruiting
344 enrolled